FindTrial
Sign In

Imvotamab

DRUG4 trials

Sponsors

IGM Biosciences, Inc.

Conditions

ArthritisArthritis, RheumatoidDLBCLFollicular LymphomaIdiopathic Inflammatory MyopathiesInflammatory MyopathiesLupus ErythematosusMantle Cell Lymphoma

Phase 1

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
TerminatedNCT04082936
IGM Biosciences, Inc.DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma +2
Start: 2019-09-30End: 2024-02-22Updated: 2024-07-24
A Study of Imvotamab in Severe Systemic Lupus Erythematosus
TerminatedNCT06041568
IGM Biosciences, Inc.Lupus Erythematosus, Systemic Lupus Erythematosus
Start: 2023-08-15End: 2025-01-27Updated: 2025-02-10
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
TerminatedNCT06087406
IGM Biosciences, Inc.Arthritis, Arthritis, Rheumatoid, Rheumatoid Arthritis
Start: 2023-03-15End: 2025-02-10Updated: 2025-02-18
A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies
TerminatedNCT06524687
IGM Biosciences, Inc.Idiopathic Inflammatory Myopathies, Inflammatory Myopathies
Start: 2024-05-29End: 2025-01-21Updated: 2025-02-11

Related Papers

Abstract CT052: A phase 1/2 randomized study of imvotamab monotherapy and in combination with loncastuximab tesirine in relapsed/refractory non-Hodgkin lymphomas
Cancer Research2023-04-141 citations
Abstract 4120: Depletion of tissue-resident B cells by a CD20xCD3 IgM bispecific T cell engager in cynomolgus monkeys demonstrates effective tissue penetration and potent target cell killing
Cancer Research2023-04-04
Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies
Blood2022-11-159 citations
Abstract CT125: A phase 1/2 randomized study of IGM-2323 in relapsed/refractory non-Hodgkin lymphomas
Cancer Research2022-06-151 citations
Abstract 4179: High valency of IGM-2323, a CD20xCD3 IgM bispecific T cell engager, displaces rituximab binding and induces potent B lymphoma cell killing
Cancer Research2022-06-151 citations
P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA
HemaSphere2022-06-012 citations
A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies
Blood2021-11-0527 citations
Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies
Blood2020-11-049 citations
Lymphoma cell-killing activity and cytokine release by CD20-directed bispecific IgM antibody-based T-cell engager (IGM-2323).
Journal of Clinical Oncology2020-05-201 citations